PMH35 – Cost-Effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France

Authors :: Doutriaux, A.
Cognet, M.
Druais, S.
Lançon, C.
Samalin, L.
Levy, P.
Godet, A.
Guillon, P.
Laboratoire d'Economie de Dauphine (LEDa)
Université Paris Dauphine-PSL
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)
Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos)
Source :: Value in Health, Value in Health, 2014, 17 (7), ⟨10.1016/j.jval.2014.08.1268⟩
Publication Year :: 2014
Publisher :: HAL CCSD, 2014.
Abstract: International audience; To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared to the most common antipsychotic strategies in France.

Subjects :: Medical care costs
JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets
[QFIN]Quantitative Finance [q-fin]
cost effectiveness analysis
economic cost
health care economics and organizations

Language :: English
Database :: OpenAIRE
Journal :: Value in Health, Value in Health, 2014, 17 (7), ⟨10.1016/j.jval.2014.08.1268⟩
Accession number :: edsair.dedup.wf.001..85dd07ba96bb6540046083c98a000638

Tools